(Reuters) -Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study.
Shares of Jazz fell about 4% to $108 in premarket trading.
While improvements were observed in patients who were treated with the drug, suvecaltamide, these were not statistically significant, the company said.
Jazz said it will further evaluate data from the study.
It is testing the drug in a separate study as a potential treatment for Parkinson’s disease-related tremors.
(Reporting by Mariam Sunny and Bhanvi Satija in Bengaluru; Editing by Mrigank Dhaniwala)
Comments